No Data
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?
NTLA Up as FDA Grants RMAT Status to Genome-Editing Therapy
JonesTrading Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $40
Promising Outlook for Intellia Therapeutics' Nex-z in ATTR-CM Treatment Backed by Safety and Patient Interest
Sector Update: Health Care Stocks Rise in Monday Afternoon Trading
Intellia Therapeutics' Nex-z Receives FDA Regenerative Medicine Advanced Therapy Designation
三和巴菲特 : Have you cried today? Baby
YWCYAPWEICHOY 叶伟财 OP 三和巴菲特 :
YWCYAPWEICHOY 叶伟财 OP 三和巴菲特 : Laughed.
71179109 : Intellia - 20% yesterday